Global Atopic Dermatitis Market: By Disease Severity (Mild, Moderate, and Severe), By Treatment Type (Corticosteroids, Antihistamines, Calcineurin Inhibitors, Immunomodulators, Biologic Therapy, PDE-4 Inhibitor, Antibiotics, Moisturizers/Emollients, and Off-Label Therapies); By Distribution Channel (Hospitals, Dermatology Clinics, Retail Pharmacy, and Online Pharmacy); By Geography (North America, Europe, Asia Pacific, MEA, and RoW), Industry Analysis, COVID-19 Impact Analysis, Size, Share, Growth, Trends, and Forecasts 2021-2028

The global Atopic Dermatitis market size is estimated at 19.3 billion USD with a CAGR of 26.8% during the forecasted period from 2021-2028.

A medical skin condition which makes one itchy and red marks on the body is known as Atopic Dermatitis. It is one of the most common type of eczema. Frequently, it affects children but has also affected adults.

The key factor driving the growth of Atopic Dermatitis market is attributed to the increasing occurrence of atopic dermatitis across the globe. In addition, growing awareness regarding healthcare along with rise in disposable income is expected to create lucrative opportunities for the growth of this market. Also, improvement of new pipeline drugs along with product approvals is significantly impacting the market size. Moreover, enhanced government reimbursement policies are likely to foster this market. Furthermore, developing healthcare infrastructure in emerging economies is anticipated to boost the market size.

The outburst of COVID-19 pandemic is estimated to have a positive impact on the growth of Atopic Dermatitis market.

On the other hand, factors such as increasing complications and risk of side effects is projected to limit the Atopic Dermatitis market.

Global Atopic Dermatitis Market– Market Dynamics

An increasing number of pipeline products for atopic dermatitis is one of the major driving factor leading to the growth of the market. The pipeline of more targeted topical and systemic therapies is expanding based on growing demand for unmet treatment of AD. The pipeline for atopic dermatitis is impressive with the majority of drugs in stage III and II. Once launched upon the successful completion of the development cycle, these drugs will boost the market growth significantly.

On the other side, The treatment of Atopic dermatitis consists of emollient therapy, and daily skin hydration, but the majority of patients still require symptomatic treatment with corticosteroids and calcineurin inhibitors,  which are associated with potential long-term side effects. Some side effects of topical treatment include- atrophy (the skin becomes thin), lichenification (the skin becomes thick, stretch marks and skin darkening.

Healthcare organizations with Established Clinical guidelines, improved care and appropriate standards for dermatological diseases is supporting the growth of Atopic Dermatitis market in the North American region.

Europe holds the second largest market share, owing to the government support for research & development and availability. This is expected to drive the European market over the forecasted period. For instance, countries like France and Germany are increasing investment in the healthcare domain.

Global Atopic Dermatitis Market Segmentation:

• By Disease Severity
  • Mild
  • Moderate
  • Severe
• By Treatment Type
  • Corticosteroids
  • Antihistamines
  • Calcineurin Inhibitors
  • Immunomodulators
  • Biologic Therapy
  • PDE-4 Inhibitor
  • Antibiotics
  • Moisturizers/Emollients
  • Off-Label Therapies
• By Distribution Channel
  • Hospitals
  • Dermatology Clinics
  • Retail Pharmacy
  • Online Pharmacy
• By Region
  • North America
  • Europe
  • Asia Pacific
  • RoW

Table of Content

• LEO Pharma
• Mylan
• Novartis
• Pfizer, Inc
• Sanofi
• Valeant